

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauDocument AM1
Appl. No. 09/891,873

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/68, C12P 19/34, C12N 9/12, C07H 21/04	A1	(11) International Publication Number: WO 98/37241 (43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/03725 (22) International Filing Date: 23 February 1998 (23.02.98) (30) Priority Data: 60/038,798 24 February 1997 (24.02.97) US 60/050,109 18 June 1997 (18.06.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/038,798 (CIP) Filed on 24 February 1997 (24.02.97) US 60/050,109 (CIP) Filed on 18 June 1997 (18.06.97) (71) Applicant (for all designated States except US): TM TECHNOLOGIES, INC. [US/US]; 82 Cummings Park, Woburn, MA 01801 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LANE, Michael, J. [US/US]; 3044 Claybourne Lane, Baldwinsville, NY 13027 (US). BENIGHT, Albert, S. [US/US]; 1630 Valley View Drive, Schaumburg, IL 60193 (US). FALDASZ, Brian, D. [US/US]; 4 Bellevue Terrace, Maynard, MA 01754 (US).		(74) Agents: DECONTI, Giulio, A., Jr. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TELOMERASE EXTENSION ASSAY (57) Abstract The invention detects the presence of telomerase activity by employing a test nucleic acid sequence that is employed as a substrate by telomerase for addition of telomeric repeat sequence. The detection of the elongation sequences indicate the presence of telomerase activity. In addition, the methods of the invention can be utilized to determine the inhibitory or enhancing effect of a compound on telomerase activity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TELOMERASE EXTENSION ASSAY

Background of the Invention

5 Telomeres are tandem repeats at the ends of eukaryotic chromosomes that appear to function in chromosome replication. Telomerase is a ribonucleoprotein enzyme that synthesizes one strand of the telomeric DNA using as a template a sequence contained within the RNA component of the enzyme. See, e.g., Blackburn (1992) *Annu. Rev. Biochem.* 61:113-129, incorporated herein by reference. Human telomerase is known to
10 synthesize telomeric repeat units with the sequence 5'-TTAGGG-3'. See, e.g., Morin (1989) *Cell*. 59:521-529, and Morin (1991) *Nature* 353:454-456, incorporated herein by reference.

 The presence of DNA telomerase has been correlated with unscheduled DNA
15 replication events such as those that occur in various cancers. For example, telomere shortening appears to dictate the number of cell divisions a normal somatic cell can undergo. Telomerase activity has also been linked to senescence. Whereas normal cells with relatively long telomeres and a senescent phenotype may contain little or no telomerase activity, tumor cells with short telomeres may have significant telomerase
20 activity. Thus, organismal senescence might be halted or at least slowed if an effective, non-toxic telomerase inhibitor can be found. Accordingly, the identification of compounds that affect telomerase activity provides important benefits to efforts at treating human diseases such as cancer.

25 Assays for the detection of cells which express telomerase have been reported (see, e.g., U.S. Patent No. 5,583,016 to Villeponteau et al.). Recently, assays which can measure telomerase levels in biopsy specimens have been reported (see, e.g., Sugino *et al.* (1996) *Int. J. Cancer* 69:301-6; Kim *et al.* (1994) *Science* 266: 2011-5). However, such assays are not always convenient or rapid, and can depend upon PCR amplification
30 of nucleic acid samples, which could result in errors. Accordingly, this invention provides methods for detection of telomerase that are easy to use and accurate.

Summary of the Invention

35 The present invention relates to methods of measuring levels of telomerase, e.g., human telomerase activity, in a variety of samples, e.g., a biological sample. The

-2-

invention also includes methods for screening compounds for their ability to modulate, e.g., to enhance or inhibit, telomerase activity, e.g., as a high throughput drug screening assay for pharmaceuticals which affect telomerase activity.

5 In one aspect, the invention provides a method for screening for compounds that modulate telomerase activity. In particular, the method can detect telomerase activity by incubating a sample that is suspected of having telomerase activity with a nucleic acid test sequence and detecting elongation of the test sequence by telomerase. The comparison of the level of telomerase activity in the absence of a test compound with the
10 level of activity in its presence can provide information regarding the inhibitory or the enhancing effects of the compound. For example, a compound shows inhibitory effects if the elongation occurs in its absence, but fails in its presence.

The preferred embodiments of the invention perform the test for telomerase
15 activity *in vitro* by employing test nucleic acid sequences, preferably DNA sequences, that are other than a preparation of genomic DNA or cDNA library. These embodiments utilize a substantially pure nucleic acid sequence that is bound to a solid substrate and is exogenously added to a sample whose telomerase activity is being investigated.

20 One aspect of the present assay relates to employing a hairpin nucleic acid sequence, having a single stranded region with a 3'-terminus, that is affixed to a solid substrate. Telomerase in presence of appropriate oligonucleotides can add telomeric repeat sequences to the 3'-terminus of the hairpin.

25 According to another aspect of the invention, the elongation of the test nucleic acid sequence is detected by adding a detector sequence that is selected to be complementary to a portion of the test sequence that includes at least one telomeric repeat sequence, thus hybridizing to this portion. The assay detects the hybridized detector sequence by providing a label, e.g., a radiolabel, in the detector sequence or
30 adding such a label to the detector sequence. For example, addition of reagents that can hybridize to a section of the detector sequence and cause chemiluminescence or color change of the sample results in detection of telomerase activity.

35 These and other aspects of the invention are described in more detail below.

Brief Description of the Drawing

FIGURE 1 is a schematic depiction of the various steps of a preferred embodiment of the telomerase assay of the invention.

Detailed Description of the Invention

The invention relates to methods for detecting telomerase activity and for screening for compounds that modulate the activity of telomerase *in vivo* or *in vitro*.

10 The methods of the invention can identify compounds which may be useful for the treatment of conditions related to activity of telomerase. The invention also relates to methods for detecting the presence or absence of telomerase activity in a sample such as a biological sample, a tissue biopsy sample or a biological fluid, e.g., blood, urine, saliva, and the like. The telomerase assays of the invention are useful for detecting
15 tissue (or other biological materials) which has telomerase activity, which may be an indicator of telomerase-linked conditions such as the presence of cancerous or precancerous cells. The invention thus provides methods for rapidly screening biological samples for conditions such as cancer.

20 In one embodiment, the invention provides a method for detecting telomerase activity in a sample. The method includes the steps of contacting a test nucleic acid sequence with a sample suspected of containing telomerase activity, under conditions such that if telomerase is present in the sample, the nucleic acid sequence is elongated by telomerase to form an elongated nucleic acid sequence, and detecting the elongated
25 nucleic acid sequence. The sample can include cells, which can be lysed if desired, under conditions such that telomerase is not denatured, i.e., such that telomerase activity is not destroyed.

In another embodiment, the invention provides a method for screening for
30 compounds capable of modulating telomerase activity. The method includes the steps of contacting a nucleic acid sequence with a sample suspected of containing a telomerase, in the presence of a test compound, under conditions such that if telomerase is present in the sample, the nucleic acid sequence is elongated by telomerase to form an elongated nucleic acid sequence in the absence of the test compound, and detecting the presence or
35 absence of the elongated nucleic acid sequence. Compounds which suppress the activity of telomerase may be useful as inhibitors of telomerase activity *in vitro*, and may

-4-

therefore be useful as inhibitors of carcinogenesis or cell senescence, as described above. Compounds which enhance the activity of telomerase in the assays of the invention may be promoters of cancer or cell senescence. Accordingly, the assays of the invention provide the ability to screen for both potentially harmful and potentially therapeutic compounds.

In preferred embodiments, methods of the invention typically employ a nucleic acid hairpin having a 3'-terminus to which telomerase can add telomeric repeat sequences. In a particularly preferred embodiment, the nucleic acid sequence (e.g., a hairpin: see W097/08183 and U.S. Patent Application No. 08/519,197) includes at least one telomeric repeat sequence as a terminal portion of the hairpin sequence (e.g., TTAGGG-3'). Telomeric repeat sequences include the human telomeric repeat sequence (5'-TTAGGG-3'), and other telomeric repeat sequences known to one of ordinary skill in the art.

FIGURE 1 shows schematically that the nucleic acid test sequence can be immobilized on a solid support. In the illustrative embodiment of FIGURE 1, the test sequence is a nucleic acid "hairpin", e.g., a nucleic acid molecule having self-complementary regions capable of hybridizing to each other to form a duplex "stem" region and, preferably, at least one dangling single-stranded portion. The advantages of immobilization of the test sequence include ease of handling, and manipulation, e.g., washing, separating, etc. The immobilization is achieved by a variety of methods known in the art. One embodiment incorporates commercially available biotinylated nucleic acid bases into the test sequence in order to attach the test sequence to a solid support that has been derivatized with avidin or streptavidin, e.g., streptavidin-coated 96-well plates, or streptavidin-coated beads such as Dynabeads, available for Dynal. Other methods for attaching or immobilizing a nucleic acid sequence on a solid support will be apparent to one of ordinary skill in the art.

In a preferred embodiment, a nucleic acid hairpin, which has been affixed to a solid support, is contacted with a sample that is suspected of having telomerase activity. As described above, telomerase is known to elongate a strand of nucleic acid by addition of telomeric repeat sequences. According to the methods of the invention, presence of telomerase activity in the sample is detected by determining whether tandemly repeated telomeric sequences have been added to the test hairpin strand. The elongation process requires the presence of appropriate oligonucleotide phosphates ("NTP"), i.e., NTPs

-5-

required for synthesis of a telomeric repeat sequence. Such NTPs can be readily purchased from commercial suppliers and are added to the reaction mixture to permit the telomerase extension reaction to proceed (e.g., human telomerase requires ATP, TTP, and GTP). Accordingly, if telomerase is present in the sample, it recognizes the 3'-terminus of the test sequence as a substrate and extends it by addition of telomeric repeat sequences. In certain embodiments, the test sequence includes a telomeric repeat sequence before addition of a sample which contains telomerase, e.g., a synthetic test sequence which is provided with a telomeric repeat sequence at the 3'-terminus by chemical synthesis. A preferred 3'-terminal portion of the test sequence is 5'-CTGGGTTAGGG-3'. In one particularly preferred embodiment, the test nucleic acid sequence has the sequence 5'-CTAGT CGACG TGGTC CTTT(biotin)T T TGGAC CACGT CGACT AGCTG GGTTA GGG-3', where the T(biotin) denotes a biotinylated thymidine.

The methods of the invention (e.g., as described in Example 1, *infra*) can detect the presence of elongated nucleic acids with sufficient sensitivity such that no target replication steps such as Polymerase Chain Reaction ("PCR") or Ligase Chain Reaction ("LCR") are required, and in a preferred embodiment no PCR or LCR steps are performed. Application of such replication methods typically involve various steps including selection of appropriate primers and necessary enzymes, heating and cooling cycles and the like. The elimination of such steps by the preferred embodiments can render the methods of the invention more convenient to use and less costly in comparison with those that utilize replication procedures. However, in certain embodiments it can be advantageous to replicate the elongated nucleic acid (or its complement) or a portion thereof, e.g., by PCR, LCR, or other known methods. For example, one may desire to incorporate such methods in the present invention if ultrasensitivity of detection of telomerase is required.

The methods of the invention detect repeat sequences added by telomerase to the nucleic acid substrate (e.g., a hairpin) by employing detection sequences that are complementary to a portion of the single-stranded region of the hairpin that includes at least one repeat sequence. The provision of a detector sequence which is complementary to a region of the hairpin as well as to at least a portion of a telomeric repeat sequence rather than to a single strand provides certain advantages. In particular, upon hybridization of the hairpin with a suitably selected detector sequence, a "nicked" duplex structure is formed, comprising contiguous regions of intramolecular hairpin:hairpin

-6-

duplex and intermolecular detector:hairpin duplex. This arrangement provides base stacking between the intramolecular duplex (i.e., the duplex "stem" of the hairpin) and the intermolecular duplex (i.e., the detector:hairpin duplex), which results in a greater sequence stringency than hybridization to a simple single strand. Further, the duplex
5 region of the hairpin stabilizes, e.g., entropically, the detector-specific region of the hairpin and thereby favors formation of a detector:hairpin duplex.

The length of the single stranded region of the hairpin can be selected to allow the use of a variety of detector sequences. In particular, if detection of only a few
10 telomeric repeat sequences is desired, it may be advantageous to select a hairpin with a relatively long single stranded region to allow stable attachment of a detector sequence that has only a few sequences that are complementary to telomeric repeat sequences.

In one embodiment, the detector sequence preferably contains at least a portion
15 which is complementary to at least two telomeric repeat sequences, e.g., the sequence 5'-CCCTAACCCTAA-3' or 5'-CCCUAACCCUAA-3'. The detector sequence also can include a poly(T), e.g., T₃₀, "tail" region that is not complementary to the hairpin. In this example, if the single stranded region of the hairpin contains the sequence 5'-TTAGGGTTAGGG-3', i.e., if the hairpin has been elongated by telomerase, the detector
20 sequence hybridizes to this segment. Excess detector sequences and non-specifically-bound detector sequences are removed by washing with a buffer having an appropriate stringency to remove unbound detector sequences while not removing specifically-bound detector molecules, as known in the art.

The hybridized detector sequences are then detected by well-known methods in
25 the art for detecting nucleic acid sequences. In some embodiments of the present invention the detector sequence contains a label, e.g., radiolabel, that allows a direct detection of the sequence. In other embodiments, the sequence is detected indirectly by attaching a label to a portion of the detector sequence which can be subsequently
30 detected by direct or indirect means. Labels can include radioisotopes, fluorophores, chemiluminescent tags and the like.

For example, European Patent Publication EP 128 332, herein incorporated by
reference, reports one such method that employs a "bridging moiety" which provides a
35 bridge between an analyte and a "signaling moiety" which provides a detectable signal. The "signal generating" portion of the signaling entity can encompass virtually any of

-7-

the signal generating systems used in the prior art. In particular, it comprises a moiety which generates a signal itself, e.g., a radiolabel, or a moiety which, upon further reaction or manipulation, will give rise to a signal, e.g., an enzyme-linked system. Some other methods utilize radioactive nucleotides in a label and detect a nucleotide sequence to which such a label has hybridized by detecting the decay of the radioactive nucleotides.

A preferred embodiment of the present invention employs a detector sequence shown in FIGURE 1 that is selected to have a poly(T) or poly(dT) "tail" to which a complementary probe sequence, i.e., poly d(A)₁₅₀₀, hybridizes. The probe sequence is chosen to be long enough so as to allow attachment of various labels in the regions that are not hybridized to the detector sequence. In particular, after removing excess polyd(A), i.e., unhybridized polyd(A), a labeled reagent such as T₂₀FITC₂ (T₂₀ = a sequence of poly (T) having 20 T units; FITC = fluorescein isothiocyanate) which can be synthesized according to known procedures, is added to the reaction mixture and it hybridizes with a portion of the polyd(A) region. After the labeling reagent is added, addition of anti-FITC-AP (conjugate of anti-FITC antibody (commercially available) with alkaline phosphatase (AP)), which specifically binds to FITC, followed by appropriate washing steps to remove excess anti-FITC-AP, provides a detectable moiety for indicating the presence of telomerase activity in the sample, e.g., by addition of a color-forming substrate for AP, followed by spectrophotometric detection of any color formation.

Example 1 provides further clarification of various steps of a preferred embodiment of the invention and is meant as illustrative and not in a limiting sense.

Example 1

In this example, a synthetic nucleic acid "hairpin" is used as a substrate for elongation by telomerase. Appropriate nucleic acid hairpins can be designed and prepared by the skilled artisan (see, e.g., U.S. Patent Application Serial No. 08/519,197, filed August 25, 1995, which is hereby incorporated by reference). Referring to Figure 1, the synthetic hairpin is first affixed to a solid support in a reaction vessel (such as a 96-well plate), e.g., through a biotin-streptavidin linkage or other means known in the art. A sample to be tested (which may contain telomerase) is then incubated with the solid-supported hairpin. Telomerase present in the sample (if any) extends the dangling

-8-

single strand of the hairpin at the 3'-terminus, attaching six base repeats of the sequence 5'-TTAGGG-3'. After the sample has been incubated in contact with the immobilized hairpins for a pre-selected period of time, the bound hairpins are (optionally) washed to remove sample, and a "detector" sequence is supplied to the reaction vessel. The
5 detector sequence includes at least one sequence which is complimentary to the telomerase extension products, i.e., the detector hybridizes to the bound hairpin only if two or more telomerase generated hexamer sequences (5'-TTAGGG-3') are present. The detector sequence preferably includes the sequence 5'-CCCTAACCCTAA-3' (or 5'-CCCUAACCCUAA-3'). In this example, the detector further include a poly(T) (e.g.,
10 T₃₀) "tail", i.e., a portion which is not complementary to the hairpin. If the bound hairpins contain the sequence 5'-TTAGGGTTAGGG-3' (i.e., have been extended by telomerase), the detector sequence (or a portion thereof) will hybridize and bind to the hairpin. Excess detector, and non-specifically-bound detector sequence, can be removed by washing with buffer of the appropriate stringency, as is known in the art.

15 A probe complementary to the poly(T) "tail" of the detector sequence, e.g., polyd(A)₁₅₀₀, is added, and hybridizes to the T₃₀ tail of the "detector" under appropriate conditions. Certain polyd(A) (or poly(A) sequences are commercially available (e.g., from Sigma Chemical Co., St. Louis, MO) or can be prepared by methods known in the art. Excess polyd(A) can be removed by washing, followed by addition of a labeled
20 reagent such as T₂₀ FITC₂, (T₂₀ = a sequence of poly (T) having 20 T units; FITC = fluorescein isothiocyanate; the T₂₀ FITC₂ reagent can be synthesized according to known procedures). After the labeling reagent is added, addition of anti-FITC-AP (conjugate of anti-FITC antibody (commercially available) with alkaline phosphatase (AP)), which specifically binds to FITC, followed by appropriate washing steps to
25 remove excess anti-FITC-AP, provides a detectable moiety for indicating the presence of telomerase activity in the sample (e.g., by addition of a color-forming substrate for AP, followed by spectrophotometric detection of any color formation). The complex of hairpin (which, in Figure 1, has been extended by telomerase present in the sample), detector, polyd(A), T₂₀ FITC₂, and anti-FITC-AP is depicted in Figure 1 as the
30 "Telomerase Extended Hairpin: Detector: Amplifier complex".

Addition of the substrate for AP results in a visible color or chemiluminescent signal, which can be read by standard methods, e.g., by spectrophotometric detection with an automated plate reader

35

-9-

Thus, the methods of the invention attain the above-mentioned objectives including detection of telomerase activity.

5 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.

The contents of all references and patent applications cited herein are hereby incorporated by reference.

10

Other embodiments are within the following claims.

What is claimed is:

-10-

1. A method for detecting telomerase activity in a sample, comprising the steps of contacting a nucleic acid sequence with a sample suspected of containing a telomerase, under conditions such that if telomerase is present in the sample, the nucleic acid
5 sequence is elongated by telomerase to form an elongated nucleic acid sequence, and detecting the elongated nucleic acid sequence.
2. The method of claim 1, wherein the nucleic acid sequence is immobilized on a solid support.
10
3. The method of claim 1, wherein the nucleic acid sequence is a nucleic acid hairpin
4. The method of claim 1, wherein the nucleic acid sequence comprises a telomeric
15 repeat sequence prior to elongation by telomerase.
5. A method for screening for compounds capable of modulating telomerase activity, comprising the steps of
contacting a nucleic acid sequence with a sample suspected of containing
20 telomerase, in the presence of a test compound, under conditions such that if telomerase is present in the sample, the nucleic acid sequence is elongated by telomerase to form an elongated nucleic acid sequence in the absence of the test compound, and detecting the presence or absence of the elongated nucleic acid sequence.

STEP 1:
AFFIX HAIRPIN
TO PLATE




FIG. 1A

STEP 2:
INCUBATE
SAMPLE WITH
HAIRPIN






FIG. 1B

2 / 2

**FIG. 1C****FIG. 1D**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/03725

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :C12Q 1/68; C12P 19/34; C12N 9/12; C07H 21/04 US CL :435/6, 91.1, 194; 536/23.1, 24.3, 24.31; 935/77.78 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.1, 194; 536/23.1, 24.3, 24.31; 935/77.78 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS: telomerase, extension		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,489,508 A (WEST et al.) 06 February 1996, claims 1, columns 44-45; column 8, line 66-column 9, line 20.	1, 5
Y	US 4,734,363 A (DATTA GUPTA et al.) 29 March 1988, column 1, lines 36-43, Figure.	1-5
Y	EP 0 297 379 A3 (MOLECULAR DIAGNOSTICS, INC.) 04 January 1989, column 2, line 47-column 3, line 12.	1-5
Y	MANIATIS et al. 'Synthesis And Cloning of cDNA' In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, pages 214-215, see entire document.	1-5
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* "A" "B" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 09 JUNE 1998		Date of mailing of the international search report 09 JUL 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer STEPHANIE W. ZITOMER, PHD Telephone No. (703) 308-0196